MERTK and cancer: Previous studies proved that MerTK is not expressed in normal B and T lymphocytes, but in neoplastic B or T lymphocytes (such as B-ALL and T-ALL) [15, 17], so MerTK may be a therapeutic target in B or T cell-derived malignant tumors.